Catumaxomab

Therapeutic indications

Catumaxomab is indicated for:

Malignant ascites with EpCAM-positive carcinomas

Population group: only adults (18 years old or older)

Catumaxomab is indicated for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg at Day 0, 20 mg at Day 3, 50 mg at Day 7, 150 mg at Day 10

Contraindications

Catumaxomab is contraindicated in the following cases:

Pregnancy

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.